Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mazdutide
- Development stage
- Phase 4
- Lead developer
- Eli Lilly
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Administration
- Subcutaneous
01
Overview
Mazdutide is a long-acting, once-weekly injectable dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed primarily for chronic weight management and type 2 diabetes. It is an analog of oxyntomodulin with a fatty acid side chain to prolong its action. Mazdutide works by activating both GLP-1R and GCGR, leading to reduced appetite, delayed gastric emptying, increased energy expenditure, enhanced fatty acid oxidation and lipolysis, improved glucose control, and reduction in liver fat content. Clinical trials have demonstrated robust weight loss effects as well as improvements in multiple cardiometabolic risk factors. The drug has been well tolerated in studies with gastrointestinal side effects being most common[1][2][4][5][7].
- Brand names
- mazdutide
- Other names
- oxyntomodulin analog
02
Targets
GLP1R (GLP-1R)GCGR (Glucagon receptor)
Beyond the preview
Go deeper on mazdutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mazdutide.